×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TNXP – tonix pharmaceuticals holding corp. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TNXP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/23
04:15 pm
tnxp
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
Low
Report
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
3/23
07:00 am
tnxp
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia
Medium
Report
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia
3/22
07:00 am
tnxp
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
Medium
Report
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
3/16
04:05 pm
tnxp
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
Low
Report
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
3/16
07:00 am
tnxp
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Low
Report
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
3/16
04:33 am
tnxp
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/13
07:00 am
tnxp
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
High
Report
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
3/8
12:03 am
tnxp
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) was upgraded by analysts at StockNews.com to a "sell" rating.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/23
04:34 pm
tnxp
Form 8-K Tonix Pharmaceuticals For: Mar 23
Low
Report
Form 8-K Tonix Pharmaceuticals For: Mar 23
3/20
05:09 pm
tnxp
Form 8-K Tonix Pharmaceuticals For: Mar 20
Medium
Report
Form 8-K Tonix Pharmaceuticals For: Mar 20
3/17
05:13 pm
tnxp
Form DEF 14A Tonix Pharmaceuticals For: May 05
Low
Report
Form DEF 14A Tonix Pharmaceuticals For: May 05
3/16
07:44 pm
tnxp
Form 4 Tonix Pharmaceuticals For: Mar 15 Filed by: Stillwell Richard Newcomb
Low
Report
Form 4 Tonix Pharmaceuticals For: Mar 15 Filed by: Stillwell Richard Newcomb
3/16
07:42 pm
tnxp
Form 3 Tonix Pharmaceuticals For: Mar 15 Filed by: Stillwell Richard Newcomb
Low
Report
Form 3 Tonix Pharmaceuticals For: Mar 15 Filed by: Stillwell Richard Newcomb
3/16
07:06 am
tnxp
Form 8-K Tonix Pharmaceuticals For: Mar 16
Medium
Report
Form 8-K Tonix Pharmaceuticals For: Mar 16
3/13
05:29 pm
tnxp
Form 8-K Tonix Pharmaceuticals For: Mar 13
Low
Report
Form 8-K Tonix Pharmaceuticals For: Mar 13
3/13
05:26 pm
tnxp
Form 10-K Tonix Pharmaceuticals For: Dec 31
Low
Report
Form 10-K Tonix Pharmaceuticals For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/26
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
80.0%
3/20 Form 8-K Tonix Pharmaceuticals For: Mar 19 70.2%
12/11 Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL 22.2%
9/5 Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 19.7%
2/4 Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences 18.1%
5/21 Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology 16.0%
11/15 Tonix Pharmaceuticals Prices $9.0 Million Public Offering 15.4%
2/28 Form 424B5 Tonix Pharmaceuticals 15.3%
3/23 Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit 15.1%
1/24 Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL 14.8%
3/20 Form 8-K Tonix Pharmaceuticals For: Mar 19 70.2%
12/11 Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL 22.2%
9/5 Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 19.7%
2/4 Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences 18.1%
5/21 Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology 16.0%
11/15 Tonix Pharmaceuticals Prices $9.0 Million Public Offering 15.4%
2/28 Form 424B5 Tonix Pharmaceuticals 15.3%
3/23 Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit 15.1%
1/24 Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL 14.8%
TOP News Decliners
2/5
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
-48.5%
2/7 Form EFFECT Tonix Pharmaceuticals -39.5%
2/27 Form 4 Tonix Pharmaceuticals For: Feb 25 Filed by: MORRIS JESSICA EDGAR -37.6%
11/4 Form 8-K Tonix Pharmaceuticals For: Nov 04 -31.9%
3/24 Form 8-K Tonix Pharmaceuticals For: Mar 24 -26.0%
11/15 Form EFFECT Tonix Pharmaceuticals -25.0%
11/20 Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD [Seeking Alpha] -22.7%
1/7 Tonix Pharmaceuticals to Present at Biotech Showcase 2020 -20.5%
7/15 Form S-1/A Tonix Pharmaceuticals -19.3%
11/25 Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference -18.6%
2/7 Form EFFECT Tonix Pharmaceuticals -39.5%
2/27 Form 4 Tonix Pharmaceuticals For: Feb 25 Filed by: MORRIS JESSICA EDGAR -37.6%
11/4 Form 8-K Tonix Pharmaceuticals For: Nov 04 -31.9%
3/24 Form 8-K Tonix Pharmaceuticals For: Mar 24 -26.0%
11/15 Form EFFECT Tonix Pharmaceuticals -25.0%
11/20 Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD [Seeking Alpha] -22.7%
1/7 Tonix Pharmaceuticals to Present at Biotech Showcase 2020 -20.5%
7/15 Form S-1/A Tonix Pharmaceuticals -19.3%
11/25 Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference -18.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: